Miami Cancer Institute Researchers Present Latest Findings at 2024 ASCO Annual Meeting
MIAMI, FL & CHICAGO, IL – April 30, 2024 – Miami Cancer Institute, part of Baptist Health South Florida, announced it will give two oral and ten poster presentations in addition to one educational session at this year’s annual meeting of the American Society of Clinical Oncology (ASCO), May 31 – June 4, at McCormick Place in Chicago, Illinois. The presentations will cover the latest research in the treatment of glioblastoma and brain metastases, breast cancer, and HPV-related cancers.
“The number and quality of our Miami Cancer Institute presentations at this year’s ASCO annual meeting is outstanding,” said Manmeet Singh Ahluwalia, M.D., MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of Miami Cancer Institute, and Fernandez Family Foundation Endowed Chair in Cancer Research. “We are excited that my colleagues and I have the opportunity to share the latest results from our research into hard-to-treat forms of brain cancer such as glioblastoma, aggressive forms of breast cancer, bladder cancer, lung cancer, brain metastases, and the latest on cancers caused by the human papillomavirus, also known as HPV.”
Miami Cancer Institute’s presentations at ASCO 2024 include:
Oral Presentations
Sunday, June 2, 2024
Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe)
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 11:36 a.m. – 11:42 a.m. CT
Location: E350
Monday, June 3, 2024
Results from METIS (EF-25), an International, Multicenter Phase III Randomized Study Evaluating the Efficacy and Safety of Tumor Treating Fields (TTFields) Therapy in NSCLC Patients with Brain Metastases
Presenter: Minesh P. Mehta, M.D.
Time: 10:24 a.m. – 10:36 a.m. CT
Location: S100bc
Poster Presentations
Saturday, June 1, 2024
A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR)
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 388a
A multicenter, randomized controlled Phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE)
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 393a
A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION)
Presenter: Rupesh R. Kotecha, M.D.
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 390a
A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE)
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 392b
A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL)
Presenter: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 371
Sunday, June 2, 2024
Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
Presenter: Vivek Podder, MBBS
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 14
Implications of HPV infection on survival outcomes in patients with penile squamous cell carcinoma: Insights from a nationwide study
Presenter: Rohan Garje, M.D.
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 451
Survival outcomes of small cell variant bladder cancer: Analysis from nationwide study
Presenter: Mohammad Arfat Ganiyani, MBBS
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 301
Treatment outcomes of brain metastasis from primary renal cell carcinoma in United States: A National Cancer Database analysis.
Presenter: Vivek Podder, MBBS
Time: 09:00 a.m. – 12:00 p.m. CT
Location: Hall A
Poster #: 256
Monday, June 3, 2024
Socioeconomic disparities in survival outcomes of patients with NSCLC with brain metastases: A real-world analysis
Presenter: Shreyas S Bellur, MBBS
Time: 01:30 p.m. – 04:30 p.m. CT
Location: Hall A
Poster #: 433
Education Session
Monday, June 3, 2024
Radiation Therapy Should Be the Default Standard of Care Option for Patients With Brain Metastases
Presenter: Minesh P. Mehta, M.D.
Time: 01:30 – 01:45 p.m. CT
Location: E350
In addition, researchers from Miami Cancer Institute such as Dr. Noah Kalman, Dr. Ana Sandoval Leon and Dr. Naomi Dempsey will also give more than half a dozen online presentations.
For updates from the 2024 ASCO Annual Meeting, look for #ASCO24 on social media and follow Miami Cancer Institute on X (Twitter) at @MiamiCancerInst.
In addition to the on-site presentations at ASCO 2024, Miami Cancer Institute’s Dr. Manmeet Ahluwalia and Dr. Reshma Mahtani will be available for interviews on the following respective studies, where they served as senior authors.
Activating HR+/HER2- and Triple Negative Breast Cancer Care Teams and Their Patients In Shared Decision-Making
Senior Author: Reshma Mahtani, D.O.
Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
Senior Author: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Phase 1 Study of BDTX-1535, an Oral 4th Generation Covalent EGFR Inhibitor, in Patients with Recurrent Glioblastoma: Preliminary Dose Escalation
Senior Author: Manmeet S. Ahluwalia, M.D., MBA, FASCO
Socioeconomic disparities in survival outcomes of patients with NSCLC with brain metastases: A real-world analysis.
Senior Author: Manmeet S. Ahluwalia, M.D., MBA, FASCO
About Miami Cancer Institute
Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK. For more information, please visit https://baptisthealth.net/services/cancer-care/miami-cancer-institute.
Miami Cancer Institute is part of Baptist Health Cancer Care, the largest cancer program in South Florida, with locations from the Florida Keys to the Palm Beaches.
###